91.81 0.00 (0.00%)
After hours: 4:54PM EDT
|Bid||87.02 x 1300|
|Ask||96.00 x 1400|
|Day's Range||90.29 - 91.96|
|52 Week Range||63.03 - 94.31|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||40.32|
|Earnings Date||Nov 1, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||95.55|
Jim Cramer says that while his "humanization of pets" thesis remains intact, the newly public Elanco Animal Health is not the way to play it.
While no analyst tracked by Bloomberg has yet rated Elanco a sell, the drugmaker for animals earned eight hold ratings, more than the five buys it received. While the company may benefit from a macro environment that includes increasing meat consumption and “humanization of pets,” Goldman Sachs analyst Jami Rubin said “the stock has gotten ahead of itself” after shares surged 36 percent through last week since a September listing at $24 per share. With the average analyst price target at $34.60, implying a return of less than 9 percent over the next twelve months, Elanco may be coming up short as investors draw comparisons to Zoetis Inc. Zoetis, the top company in medicines for pets and cattle, has seen its shares more than triple since their debut in 2013.
Investors are waiting to find out if Wall Street analysts will predict still greater returns for Elanco, which has already rallied 36 percent since its Sept. 20 debut. A quiet period that ends Monday allows banks which underwrote the IPO, including Goldman Sachs, JPMorgan Chase and Morgan Stanley, to start coverage. Other underwriters included BNP Paribas, Bank of America Merrill Lynch, Barclays Capital, Citigroup, Cowen & Co, Credit Suisse, Deutsche Bank and Evercore.
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to business plans or prospects, future operating or financial performance, future use of cash and dividend payments, and other future events.
Worried about what a pickup in inflation could do to your investments? Jeff Reeves offers five picks.,
The Zacks Analyst Blog Highlights: Champions Oncology, CytoDyn, Infinity Pharmaceuticals, Nektar Therapeutics and Zoetis
Zoetis Inc. will host a webcast and conference call at 8:30 a.m. on Thursday, Nov. 1, 2018. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Glenn David will review third quarter 2018 financial results and respond to questions from financial analysts during the call.
In September, nine analysts are covering Idexx Laboratories (IDXX). Six analysts gave Idexx stock a “buy” or higher rating, and three analysts gave Idexx a “hold” rating. The mean rating for Idexx stock is 1.89 with a target price of $264.80, implying an upside potential of 9.1% over Idexx’s closing price of $242.71 on September 24.
Idexx Laboratories (IDXX) incurred general and administrative expenses of $61.08 million in the second quarter, compared with $55.46 million in the second quarter of 2017. Its sales and marketing expenses increased from $87.69 million in the second quarter of 2017 to $96.25 million in the second quarter due to increased personnel-related costs. Its research and development expenses increased from $26.9 million in the second quarter of 2017 to $29.51 million in the second quarter.
Idexx Laboratories’ (IDXX) products and services cater to the companion animal, veterinary, livestock, poultry, dairy, and water testing markets. The company also sells portable electrolytes and blood gas analyzers. So far in 2018, Idexx Laboratories stock has generated more than 50.0% returns for investors.
CNBC's Jim Cramer says that while his "humanization of pets" thesis remains intact, the newly public Elanco Animal Health is not the way to play it. While the former Eli Lilly subsidiary has intriguing prospects, Cramer can't recommend its stock at its current highs. CNBC's Jim Cramer has long backed the "humanization of pets" theory — the notion that how much people spend on their pets is continually rising — but the latest animal-focused entrant to the public market did not fit Cramer's bill.
Zoetis Inc. (ZTS) will participate in the 2018 Cantor Global Healthcare Conference on Monday, Oct. 1, 2018, in New York, N.Y. Clint Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Genetics and Aquatic Health, will represent the company and respond to questions from analysts. Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services.
Zoetis is the IBD Stock Of The Day as shares of Fido's drugmaker loomed near a buy point Friday after rival Elanco Animal Health began its second day of trading.
The company raised $1.51 billion from the offering, which it expects to largely pass on to Eli Lilly and Co (LLY.N). The U.S. drugmaker is expected to own about 82.3 percent of Elanco after the IPO, which was announced in July following a nine-month review of Lilly's businesses which include diabetes and lung cancer drugs.
The Eli Lilly & Co.-owned animal medicine maker rose to $32.11 from its $24 offering price at 11:40 a.m. Thursday in New York trading, giving it a market value of $11.7 billion. Elanco priced 62.9 million shares on Wednesday, after marketing them at $20 to $23 each. Elanco already operates fairly independently from its soon-to-be former parent, which will help it move quickly once it’s on its own, according to Chief Executive Officer Jeff Simmons.
Year-to-date, Zoetis (ZTS) stock has been on an upward trajectory, rising from $71.77 on January 2 to a high of $93.23 on August 8. In September, Zoetis stock has corrected to $89.06 as of September 5.